NK Cell Compartments and Their Activation by Dendritic Cells

Journal of Immunology

Volumn 172, Issue 3, 2004, Pages 1333-1339

  Ferlazzo, Guido ^a,b   Münz, Christian ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; B LYMPHOCYTE; CANCER PATIENT; CELL ACTIVATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMORAL IMMUNITY; IMMUNOSTIMULATION; LEUKEMIA; LOW DRUG DOSE; LYMPHOID ORGAN; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 1642444661     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.3.1333     Document Type: Review

References (87)

1. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Immunol. 47:187.
2. Biron, C. A., K. B. Nguyen, G. C. Pien, L. P. Cousens, and T. P. Salazar-Mather. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 171:189.
3. Robertson, M. J., and J. Ritz. 1990. Biology and clinical relevance of human natural killer cells. Blood 76:2421.
4. + NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J. Immunol. 166:6477.
5. dim NK cells. Eur. J. Immunol. 31:3121.
6. bright subset. Blood 97:3146.
7. Moretta, A., C. Bottino, M. Vitale, D. Pende, C. Cantoni, M. C. Mingari, R. Biassoni, and L. Moretta. 2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19:197.
8. Moretta, L., G. Ferlazzo, M. C. Mingari, G. Melioli, and A. Moretta. 2003. Human natural killer cell function and their interactions with dendritic cells. Vaccine 21(Suppl. 2):S38.
9. Moretta, L., C. Bottino, D. Pende, M. C. Mingari, R. Biassoni, and A. Moretta. 2002. Human natural killer cells: their origin, receptors and function. Eur. J. Immunol. 32:1205.
10. Bauer, S., V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T. Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727.
11. Cosman, D., J. Mullberg, C. L. Sutherland, W. Chin, R. Armitage, W. Fanslow, M. Kubin, and N. J. Chalupny. 2001. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123.
12. Lanier, L. L. 1998. NK cell receptors. Annu. Rev. Immunol. 16:359.
13. bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101:3052.
14. Westermann, J., and R. Pabst. 1992. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin. Invest. 70:539.
15. Ttepel, F. 1974. Number and distribution of lymphocytes in man: a critical analysis. Klin. Wochenschr. 52:511.
16. Fernandez, N. C., A. Loziet, C. Flament, P. Ricciatdi-Castagnoli, D. Bellet, M. Suter, M. Perticaudet, T. Tursz, E. Maraskovsky, and L. Zitvogel. 1999. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5:405.
17. Ferlazzo, G., M. L. Tsang, L. Moretta, G. Melioli, R. M. Steinman, and C. Münz. 2002. Human dendritic cells activate resting NK cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195:343.
18. Gerosa, F., B. Baldani-Guerra, C. Nisii, V. Marchesini, G. Carra, and G. Trinchieri. 2002. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195:327.
19. Ferlazzo, G., B. Morandi, A. D'Agostino, R. Meazza, G. Melioli, A. Moretta, and L. Moretta. 2003. The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur. J. Immunol. 33:306.
20. Piccioli, D., S. Sbrana, E. Melandri, and N. M. Valiante. 2002. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 195:335.
21. + blood dendritic cells enhance NK cell-mediated cytotoxicity. Eur. J. Immunol. 31:2633.
22. + cell-derived NK cell cytotoxicity by dendritic cells. J. Immunol. 166:1590.
23. Andrews, D. M., A. A. Scalzo, W. M. Yokoyama, M. J. Smyth, and M. A. Degli-Esposti. 2003. Functional interactions between dendritic cells and NK cells during viral infection. Nat. Immunol. 4:175.
24. Orange, J. S., and C. A. Biron. 1996. An absolute and restricted requirement for IL-12 in natural killer cell IFN-γ production and antiviral defense: studies of natural killer and T cell responses in contrasting viral infections. J. Immunol. 156:1138.
25. Dalod, M., T. Hamilton, R. Salomon, T. P. Salazar-Mather, S. C. Henry, J. D. Hamilton, and C. A. Biron. 2003. Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon α/β. J. Exp. Med. 197:885.
26. Nguyen, K. B., T. P. Salazar-Mather, M. Y. Dalod, J. B. Van Deusen, X. Q. Wei, F. Y. Liew, M. A. Caligiuri, J. E. Durbin, and C. A. Biron. 2002. Coordinated and distinct roles for IFN-αβ, IL-12, and IL-15 regulation of NK cell responses to viral infection. J. Immunol. 169:4279.
27. Granucci, F., C. Vizzardelli, N. Pavelka, S. Feau, M. Persico, E. Virzi, M. Rescigno, G. Moro, and P. Ricciardi-Castagnoli. 2001. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat. Immunol. 2:882.
28. Granucci, F., S. Feau, V. Angeli, F. Trottein, and P. Ricciardi-Castagnoli. 2003. Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming. J. Immunol. 170:5075.
29. Wilson, J. L., L. C. Heffler, J. Charo, A. Scheynius, M. T. Bejarano, and H. G. Ljunggren. 1999. Targeting of human dendritic cells by autologous NK cells. J. Immunol. 163:6365.
30. Carbone, E., G. Terrazzano, G. Ruggiero, D. Zanzi, A. Ottaiano, C. Manzo, K. Karre, and S. Zappacosta. 1999. Recognition of autologous dendritic cells by human NK cells. Eur. J. Immunol. 29:4022.
31. Spaggiari, G. M., R. Carosio, D. Pende, S. Marcenaro, P. Rivera, M. R. Zocchi, L. Moretta, and A. Poggi. 2001. NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46. Eur. J. Immunol. 31:1656.
32. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097.
33. Ferlazzo, G., C. Semino, and G. Melioli. 2001. HLA class I molecule expression is up-regulated during maturation of dendritic cells, protecting them from natural killer cell-mediated lysis. Immunol. Lett. 76:37.
34. Della Chiesa, M., M. Vitale, S. Carlomagno, G. Ferlazzo, L. Moretta, and A. Moretta. 2003. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur. J. Immunol. 33:1657.
35. Poggi, A., R. Carosio, G. M. Spaggiari, C. Fortis, G. Tambussi, G. Dell'Antonio, E. Dal Cin, A. Rubartelli, and M. R. Zocchi. 2002. NK cell activation by dendritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 Tat C-terminal domain. J. Immunol. 168:95.
36. Buentke, E., L. C. Heffler, J. L. Wilson, R. P. Wallin, C. Lofman, B. J. Chambers, H. G. Ljunggren, and A. Scheynius. 2002. Natural killer and dendritic cell contact in lesional atopic dermatitis skin-Malassezia-influenced cell interaction. J. Invest. Dermatol. 119:850.
37. Bazan, J. F., K. B. Bacon, G. Hardiman, W. Wang, K. Soo, D. Rossi, D. R. Greaves, A. Zlotnik, and T. J. Schall. 1997. A new class of membrane-bound chemokine with a CX3C motif. Nature 385:640.
38. Hoffmann, E., O. Dittrich-Breiholz, H. Holtmann, and M. Kracht. 2002. Multiple control of interleukin-8 gene expression. J. Leukocyte Biol. 72:847.
39. + cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J. Immunol. 168:6173.
40. Cooper, M. A., T. A. Fehniger, and M. A. Caligiuri. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22:633.
41. Dowdell, K. C., D. J. Cua, E. Kirkman, and S. A. Stohlman. 2003. NK cells regulate CD4 responses prior to antigen encounter. J. Immunol. 171:234.
42. Biton, C. A., K. S. Byton, and J. L. Sullivan. 1989. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320:1731.
43. + T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro. J. Virol. 76:5071.
44. Masucci, M. G., M. T. Bejarano, G. Masucci, and E. Klein. 1983. Large granular lymphocytes inhibit the in vitro growth of autologous Epstein-Barr virus-infected B cells. Cell. Immunol. 76:311.
45. Thorley-Lawson, D. A., L. Chess, and J. L. Strominger. 1977. Suppression of in vitro Epstein-Barr virus infection: a new role for adult human T lymphocytes. J. Exp. Med. 146:495.
46. Baiocchi, R. A., J. S. Ward, L. Carrodeguas, C. F. Eisenbeis, R. Peng, S. Roychowdhury, S. Vourganti, T. Sekula, M. O'Brien, M. Moeschberger, and M. A. Caligiuri. 2001. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. J. Clin. Invest. 108:887.
47. Shellam, G. R., J. E. Allan, J. M. Papadimitriou, and G. J. Bancroft. 1981. Increased susceptibility to cytomegalovirus infection in beige mutant mice. Proc. Natl. Acad. Sci. USA 78:5104.
48. Brown, M. G., A. O. Dokun, J. W. Heusel, H. R. Smith, D. L. Beckman, E. A. Blattenberger, C. E. Dubbelde, L. R. Stone, A. A. Scalzo, and W. M. Yokoyama. 2001. Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science 292:934.
49. Daniels, K. A., G. Devora, W. C. Lai, C. L. O'Donnell, M. Bennett, and R. M. Welsh. 2001. Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H. J. Exp. Med. 194:29.
50. Lee, S. H., S. Girard, D. Macina, M. Busa, A. Zafer, A. Belouchi, P. Gros, and S. M. Vidal. 2001. Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. Nat. Genet. 28:42.
51. Salazar-Mather, T. P., J. S. Orange, and C. A. Biron. 1998. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1α (MIP-1α)-dependent pathways. J. Exp. Med. 187:1.
52. Salazar-Mather, T. P., C. A. Lewis, and C. A. Biron. 2002. Type I interferons regulate inflammatory cell trafficking and macrophage inflammatory protein 1 α delivery to the liver. J. Clin. Invest. 110:321.
53. Salazar-Mather, T. P., T. A. Hamilton, and C. A. Biron. 2000. A chemokine-to-cytokine-to-chemokine cascade critical in antiviral defense. J. Clin. Invest. 105:985.
54. Craigen, J. L., and J. E. Grundy. 1996. Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is nor prevented by ganciclovir or foscarnet treatment. Transplantation 62:1102.
55. Craigen, J. L., K. L. Yong, N. J. Jordan, L. P. MacCormac, J. Westwick, A. N. Akbar, and J. E. Grundy. 1997. Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration. Immunology 92:138.
56. Almeida-Porada, G., C. D. Porada, J. D. Shanley, and J. L. Ascensao. 1997. Altered production of GM-CSF and IL-8 in cytomegalovirus-infected, IL-1-primed umbilical cord endothelial cells. Exp. Hematol. 25:1278.
57. Murayama, T., Y. Ohara, M. Obuchi, K. S. Khabar, H. Higashi, N. Mukaida, and K. Matsushima. 1997. Human cytomegalovirus induces interleukin-8 production by a human monocytic cell line, THP-1, through acting concurrently on AP-1- and NF-κB-binding sites of the interleukin-8 gene. J. Virol. 71:5692.
58. Moretta, A., S. Sivori, M. Vitale, D. Pende, L. Morelli, R. Augugliaro, C. Bottino, and L. Moretta. 1995. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J. Exp. Med. 182:875.
59. Biassoni, R., C. Cantoni, M. Falco, S. Verdiani, C. Bottino, M. Vitale, R. Conte, A. Poggi, A. Moretta, and L. Moretta. 1996. The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J. Exp. Med. 183:645.
60. Bottino, C., S. Sivori, M. Vitale, C. Cantoni, M. Falco, D. Pende, L. Morelli, R. Augugliaro, G. Semenzato, R. Biassoni, et al. 1996. A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation. Eur. J. Immunol. 26:1816.
61. Pende, D., P. Rivera, S. Marcenaro, C. C. Chang, R. Biassoni, R. Conte, M. Kubin, D. Cosman, S. Ferrone, L. Moretta, and A. Moretta. 2002. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 62:6178.
62. Moretta, A., R. Biassoni, C. Bottino, M. C. Mingari, and L. Moretta. 2000. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol. Today 21:228.
63. Vitale, M., C. Bottino, S. Sivori, L. Sanseverino, R. Castriconi, E. Marcenaro, R. Augugliaro, L. Moretta, and A. Moretta. 1998. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187:2065.
64. Diefenbach, A., and D. H. Raulet. 2001. Strategies for target cell recognition by natural killer cells. Immunol. Rev. 181:170.
65. Sutherland, C. L., N. J. Chalupny, and D. Cosman. 2001. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions. Immunol. Rev. 181:185.
66. Salih, H. R., H. G. Rammensee, and A. Steinle. 2002. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169:4098.
67. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734.
68. Salih, H. R., H. Antropius, F. Gieseke, S. Z. Lutz, L. Kanz, H. G. Rammensee, and A. Steinle. 2003. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102:1389.
69. Salih, H. R., H. Antropius, H. G. Rammensee, and A. Steinle. 2002. Expression of MICA and MICB, ligands of the immunoreceptor NKG2D, on leukemia cells: cell surface release and triggering of anti-leukemia activity of cytotoxic lymphocytes. Blood 100:549a.
70. Groh, V., R. Rhinehart, J. Randolph-Habecker, M. S. Topp, S. R. Riddell, and T. Spies. 2001. Costimulation of CD8 αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2:255.
71. Tieng, V., C. Le Bouguenec, L. du Merle, P. Bertheau, P. Desreumaux, A. Janin, D. Charron, and A. Toubert. 2002. Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc. Natl. Acad. Sci. USA 99:2977.
72. Diefenbach, A., E. R. Jensen, A. M. Jamieson, and D. H. Raulet. 2001. Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165.
73. Morra, M., D. Howie, M. S. Grande, J. Sayos, N. Wang, C. Wu, P. Engel, and C. Terhorst. 2001. X-linked lymphoproliferative disease: a progressive immunodeficiency. Annu. Rev. Immunol 19:657.
74. Parolini, S., C. Bottino, M. Falco, R. Augugliaro, S. Giliani, R. Franceschini, H. D. Ochs, H. Wolf, J. Y. Bonnefoy, R. Biassoni, et al. 2000. X-linked lymphoproliferative disease: 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J. Exp. Med. 192:337.
75. Latchman, Y., P. F. McKay, and H. Reiser. 1998. Cutting edge: identification of the 2B4 molecule as a counter-receptor for CD48. J. Immunol. 161:5809.
76. Brown, M. H., K. Boles, P. A. van der Merwe, V. Kumar, P. A. Mathew, and A. N. Barclay. 1998. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J. Exp. Med. 188:2083.
77. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
78. Steinman, R. M., D. Hawiger, and M. C. Nussenzweig. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21:685.
79. Parronchi, P., M. De Carli, R. Manetti, C. Simonelli, S. Sampognaro, M. P. Piccinni, D. Macchia, E. Maggi, G. Del Prete, and S. Romagnani. 1992. IL-4 and IFN (α and γ) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J. Immunol. 149:2977.
80. Bradley, L. M., D. K. Dalton, and M. Croft. 1996. A direct role for IFN-γ in regulation of Th1 cell development. J. Immunol. 157:1350.
81. Coudert, J. D., C. Coureau, and J. C. Guery. 2002. Preventing NK cell activation by donor dendritic cells enhances allospecific CD4 T cell priming and promotes Th type 2 responses to transplantation antigens. J. Immunol. 169:2979.
82. Velardi, A., L. Ruggeri, A. Moretta, and L. Moretta. 2002. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol. 23:438.
83. Caligiuri, M. A., C. Murray, M. J. Robertson, E. Wang, K. Cochran, C. Cameron, P. Schow, M. E. Ross, T. R. Klumpp, R. J. Soiffer, et al. 1993. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J. Clin. Invest. 91:123.
84. Fehniger, T. A., E. M. Bluman, M. M. Porter, E. Mrozek, M. A. Cooper, J. B. VanDeusen, S. R. Frankel, W. Stock, and M. A. Caligiuri. 2000. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J. Clin. Invest. 106:117.
85. Ferlazzo, G., D. Thomas, S.-L. Lin, K. Goodman, B. Morandi, W. A. Muller, A. Moretta, and C. Münz. 2003. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J. Immunol. 172:1455.
86. Jinushi, M., T. Takehara, T. Kanto, T. Tatsumi, V. Groh, T. Spies, T. Miyagi, T. Suzuki, Y. Sasaki, and N. Hayashi. 2003. Critical role of MHC class I-related chain A and B expression on IFN-α-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J. Immunol. 170:6249.
87. Jinushi, M., T. Takehara, T. Tatsumi, T. Kanto, V. Groh, T. Spies, T. Suzuki, T. Miyagi, and N. Hayashi. 2003. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J. Immunol. 171:5423.